Data from the TRANSCEND-FL trial support the accelerated approval of lisocabtagene maraleucel in relapsed/refractory follicular lymphoma.
Approval Alert | Lisocabtagene Maraleucel in Relapsed/Refractory Follicular Lymphoma
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: The Top 10 Takeaways for Hematologic Oncology Care
2
How Should a Patient With Multiple Myeloma Manage Talquetamab’s Toxicity?
3
QOL Improvement in Breast Cancer Noted With YES System
4
What is Cevostamab’s Mechanism of Action in Multiple Myeloma?
5
